Loading the SOTA2 catalog…
BrainSee
First FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI) by combining a patien...
What is BrainSee?
First FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI) by combining a patient's brain MRI with cognitive test scores to generate a likelihood score for progression to Alzheimer's dementia.
Product typeDiagnostics & Imaging
Pricing ·
Deployment
APINot available
What teams use BrainSee for
Early detection of Alzheimer's disease
Monitoring patient-specific response to interventions
Advancing drug development for Alzheimer's disease
Integrations and access
Platforms, integrations, and language support vary by plan and region. Confirm final requirements with the vendor.
Platforms
IntegrationsAPI and webhooks
Languages
Support
What reviewers say
Community reviewsReviews are owned and editable by their authors.
Sign in to reviewLoading community reviews…
Enterprise readiness
Compliance claims are normalized from current vendor documentation and independently reviewed by SOTA2.
FDA De Novo Approval
FDA Breakthrough Designation
Data retention:
Benchmarks and comparisons
Independent benchmarksStructured task results are being verified.
Side-by-side comparisonsComparison workspaces will be available in a later release.
